Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 10:13:839972.
doi: 10.3389/fphar.2022.839972. eCollection 2022.

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children

Valeria Dipasquale  1 , Giuseppe Cicala  2 , Edoardo Spina  2 , Claudio Romano  1
Affiliations
Review

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children

Valeria Dipasquale et al. Front Pharmacol. .

Abstract

Proton pump inhibitors (PPIs) are among the most prescribed drugs worldwide and include omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole. Their use in pediatrics is approved for children older than 1 year, for the short-term treatment of symptomatic gastroesophageal reflux disease (GERD), healing of erosive esophagitis, treatment of peptic ulcer disease, and eradication of Helicobacter pylori. PPIs are also considered the standard of care for pediatric eosinophilic esophagitis. Despite the strict range of indications, the use of this class of molecules has increased in all pediatric age ranges. The long-term gastric acid suppression in children has been linked to increased risks of gastrointestinal and lower respiratory tract infections, bone fractures, and allergy. This study aims to provide a comprehensive overview of the mechanism of actions, use (and misuse) in infants and children, and safety of PPIs.

Keywords: adverse reaction; indication; pediatrics; proton pump inhibitor; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Adamko D. J., Majaesic C. M., Skappak C., Jones A. B. (2012). A Pilot Trial on the Treatment of Gastroesophageal Reflux-Related Cough in Infants. Zhongguo Dang Dai Er Ke Za Zhi 14, 321–327. 10.3978/j.issn.2224-4336.2012.03.03 - DOI - PubMed
    1. Anjewierden S., Han Z., Foster C. B., Pant C., Deshpande A. (2019). Risk Factors for Clostridium difficile Infection in Pediatric Inpatients: a Meta-Analysis and Systematic Review. Infect. Control Hosp. Epidemiol. 40, 420–426. 10.1017/ice.2019.23 - DOI - PubMed
    1. Arias Á., Pérez-Martínez I., Tenías J. M., Lucendo A. J. (2016). Systematic Review with Meta-Analysis: the Incidence and Prevalence of Eosinophilic Oesophagitis in Children and Adults in Population-Based Studies. Aliment. Pharmacol. Ther. 43, 3–15. 10.1111/apt.13441 - DOI - PubMed
    1. Aznar-Lou I., Reilev M., Lødrup A. B., Rubio-Valera M., Haastrup P. F., Pottegård A. (2019). Use of Proton Pump Inhibitors Among Danish Children: a 16-year Register-Based Nationwide Study. Basic Clin. Pharmacol. Toxicol. 124, 704–710. 10.1111/bcpt.13191 - DOI - PubMed
    1. Baker R., Tsou V. M., Tung J., Baker S. S., Li H., Wang W., et al. (2010). Clinical Results from a Randomized, Double-Blind, Dose-Ranging Study of Pantoprazole in Children Aged 1 through 5 Years with Symptomatic Histologic or Erosive Esophagitis. Clin. Pediatr. (Phila) 49, 852–865. 10.1177/0009922810369253 - DOI - PubMed

LinkOut - more resources